TRIM63 and sarcopenia: PMI5011-mediated enhanced insulin signaling, coupled with decreased MuRF-1 expression, decreased 26S proteasome activity and larger myofiber size in the obesity-related insulin resistant animals indicates PMI5011 has therapeutic potential for preserving muscle mass in insulin resistant skeletal muscle, including treatment of muscle loss due to sarcopenia.